Abstract
Background Newborn screening (NBS) programmes identify a wide range of disease phenotypes, which raises the question whether early identification and treatment is beneficial for all. This study aims to answer this question for primary carnitine deficiency (PCD) taking into account that NBS for PCD identifies newborns with PCD and also until then undiagnosed mothers. Methods We investigated clinical, genetic (variants in SLC22A5 gene) and functional (carnitine transport activity in fibroblasts) characteristics of all referred individuals through NBS (newborns and mothers) and clinically diagnosed patients with PCD (not through NBS). Disease phenotype in newborns was predicted using data from PCD mothers and cases published in literature with identical SLC22A5 variants. Results PCD was confirmed in 19/131 referred newborns, 37/82 referred mothers and 5 clinically diagnosed patients. Severe symptoms were observed in all clinically diagnosed patients, 1 newborn and none of the mothers identified by NBS. PCD was classified as severe in all 5 clinically diagnosed patients, 3/19 newborns and 1/37 mothers; as benign in 8/19 newborns and 36/37 mothers and as unknown in 8/19 newborns. Carnitine transport activity completely separated severe phenotype from benign phenotype (median (range): 4.0% (3.5-5.0)] vs 26% (9.5-42.5), respectively). Conclusion The majority of mothers and a significant proportion of newborns with PCD identified through NBS are likely to remain asymptomatic without early treatment. Conversely, a small proportion of newborns with predicted severe PCD could greatly benefit from early treatment. Genetic variants and carnitine transport activity can be used to distinguish between these groups. & amp; copy; & amp; copy; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
Original language | English |
---|---|
Pages (from-to) | 1177-1185 |
Number of pages | 9 |
Journal | Journal of Medical Genetics |
Volume | 60 |
Issue number | 12 |
Early online date | 1 Jul 2023 |
DOIs | |
Publication status | Published - 1 Dec 2023 |
Keywords
- Neonatal Screening
- Pathological Conditions
- Signs and Symptoms
- Pediatrics
- Human Genetics
- Public Health
- TRANSPORTER DEFECT
- MUTATIONS
- OCTN2
- CARDIOMYOPATHY
- IDENTIFICATION
- PHENOTYPE